
BSRBR-RA Review of 2024
2024 has been another great year for BSRBR-RA. Weβre very grateful to the NHS professionals who provide data, and to the participants. The data provided is integral to the success of the research.
Our year in numbers
Our publications this year
- Association between body weight and tocilizumab effectiveness in rheumatoid arthritis.
- Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of RA Registers (JAK-POT).
- Potential impact of European Medicines Agency measures to minimise risk of serious side effects on JAKi prescribing and utilisation in the UK.
Looking forward to 2025Β
Our priorities are β
- Recruitment of all eligible patients to the study, particularly those starting JAKi therapies.
- Follow up data collection.
- Patient questionnaire data collection, which is re-starting in an electronic format this year.
- Meeting NHS professionals at the BSR conference in April β if you are attending, please get in touch to arrange a catch up with us./
Again, thank you to everyone who contributes to the BSRBR-RA Study.
Happy New Year!
0 Comments